Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises GB HoldCo on its takeover bid for Gunnebo
Mandate

Vinge advises GB HoldCo on its takeover bid for Gunnebo

September 28, 2020 Banking and Finance Commercial Agreements EU, Competition and Regulatory Capital Markets and Public M&A M&A IT, Telecommunications and Outsourcing Intellectual Property

Altor Fund V and Stena Adactum AB have, through the jointly controlled company GB HoldCo AB, announced a recommended cash offer to the shareholders of Gunnebo Aktiebolag. The offer values Gunnebo at approximately SEK 2.4 billion.

Gunnebo develops, manufactures, markets and sells security products, software and services. The Company has its headquarters in Gothenburg with operations globally through own presence in approximately 25 countries. In addition, Gunnebo's products and solutions are sold in more than 100 markets through comprehensive distribution networks.

Vinge’s team consisted of David Andersson, Erik Sjöman, Amanda Knutsson and Julia Hirschberg (Capital Markets and Public M&A), Christina Kokko, Maria Dahlin Kolvik, Desirée Sjöblom, Elsie Nassar and Carl Fredrik Wachtmeister (M&A), Louise Brorsson Salomon, Linn Adelwald, Pauline Lagerstrand and Hannes Pettersson (Banking and Finance) Johan Karlsson and Johan Wahlbom (Competition law), Sofia Bergenstråhle (IP), Karl-Hugo Engdahl (IT) and Jolene Reimerson (Commercial Agreements).

Related

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024

Vinge advises Triton in connection with the divestment of Norstat to Nalka Invest

Vinge advises Triton Smaller Mid-Cap Fund I (“Triton”) in connection with the divestment of Norstat, a leading data collector for market research, to Nalka Invest.
April 12, 2024